Print this page    •   Back to Web version of article

Drugs Used in the Treatment of HIV Infection

January 2008

Multi-Class Combination Products

Brand NameGeneric NamesManufacturer NameApproval DateTime to Approval
Atriplaefavirenz, emtricitabine and tenofovir disoproxil fumarateBristol-Myers Squibb and Gilead Sciences12-July-062.5 months


Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Brand NameGeneric Name(s)Manufacturer NameApproval DateTime to Approval
Combivirlamivudine and zidovudineGlaxoSmithKline27-Sep-973.9 months
Emtrivaemtricitabine, FTCGilead Sciences02-Jul-0310 months
Epivirlamivudine, 3TCGlaxoSmithKline17-Nov-954.4 months
Epzicomabacavir and lamivudineGlaxoSmithKline02-Aug-0410 months
Hividzalcitabine, dideoxycytidine, ddCHoffmann-La Roche19-Jun-927.6 months
Retrovirzidovudine, azidothymidine, AZT, ZDVGlaxoSmithKline19-Mar-873.5 months
Trizivirabacavir, zidovudine and lamivudineGlaxoSmithKline14-Nov-0010.9 months
Truvadatenofovir disoproxil fumarate and emtricitabineGilead Sciences, Inc.02-Aug-045 months
Videx ECenteric coated didanosine, ddI ECBristol Myers-Squibb31-Oct-009 months
Videxdidanosine, dideoxyinosine, ddIBristol Myers-Squibb9-Oct-916 months
Vireadtenofovir disoproxil fumarate, TDFGilead26-Oct-015.9 months
Zeritstavudine, d4TBristol Myers-Squibb24-Jun-945.9 months
Ziagenabacavir sulfate, ABCGlaxoSmithKline17-Dec-985.8 months


Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
IntelenceetravirineTibotec Therapeutics18-Jan-086 months
Rescriptordelavirdine, DLVPfizer4-Apr-978.7 months
Sustivaefavirenz, EFVBristol Myers-Squibb17-Sep-983.2 months
Viramunenevirapine, NVPBoehringer Ingelheim21-Jun-963.9 months


Protease Inhibitors (PIs)

Brand NameGeneric Name(s)Manufacturer NameApproval DateTime to Approval
Ageneraseamprenavir, APVGlaxoSmithKline15-Apr-996 months
Aptivustipranavir, TPVBoehringer Ingelheim22-Jun-056 months
Crixivanindinavir, IDVMerck13-Mar-961.4 months
Fortovasesaquinavir (no longer marketed)Hoffmann-La Roche7-Nov-975.9 months
Invirasesaquinavir mesylate, SQVHoffmann-La Roche6-Dec-953.2 months
Kaletralopinavir and ritonavir, LPV/RTVAbbott Laboratories15-Sep-003.5 months
LexivaFosamprenavir Calcium, FOS-APVGlaxoSmithKline20-Oct-0310 months
Norvirritonavir, RTVAbbott Laboratories1-Mar-962.3 months
PrezistadarunavirTibotec, Inc.23-Jun-066 months
Reyatazatazanavir sulfate, ATVBristol-Myers Squibb20-Jun-036 months
Viraceptnelfinavir mesylate, NFVAgouron Pharmaceuticals14-Mar-972.6 months


Fusion Inhibitors

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
Fuzeonenfuvirtide, T-20Hoffmann-La Roche & Trimeris13-Mar-036 months


Entry Inhibitors -- CCR5 Co-Receptor Antagonist

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
SelzentrymaravirocPfizer06-August-078 months


HIV Integrase Strand Transfer Inhibitors

Brand NameGeneric NameManufacturer NameApproval DateTime to Approval
IsentressraltegravirMerck & Co., Inc.12-Oct-076 months




This article was provided by U.S. Food and Drug Administration. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/treat/art13875.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.